<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01654484</url>
  </required_header>
  <id_info>
    <org_study_id>33-001</org_study_id>
    <nct_id>NCT01654484</nct_id>
  </id_info>
  <brief_title>A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT</brief_title>
  <official_title>A Phase I/II, Randomized, Observer-masked, Placebo-and Active-controlled, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santen Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and efficacy of up to three
      concentrations of DE-117 ophthalmic solution (Low Dose, Medium Dose, and High Dose) as
      monotherapy and as adjunctive therapy (DE-117 ophthalmic solution with 0.0015% tafluprost) in
      subjects with primary open-angle glaucoma or ocular hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two stage study.

      Stage One will explore the dose response of three concentrations of DE-117 as monotherapy
      compared with 0.0015% tafluprost and placebo. The safety and efficacy of DE-117 as adjunctive
      therapy (with 0.0015% tafluprost) compared with 0.0015% tafluprost and placebo will also be
      evaluated. In addition, the additive effect of adjunctive therapy of each concentration will
      be compared with the corresponding monotherapy concentration.

      Stage Two will assess the safety and efficacy of the optimal DE-117 concentration as
      monotherapy compared with 0.0015% tafluprost. The safety and efficacy of the optimal DE-117
      concentration as adjunctive therapy (with 0.0015% tafluprost) compared with DE-117
      monotherapy and 0.0015% tafluprost will also be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in intraocular pressure (IOP) on Day 29 at each scheduled time point</measure>
    <time_frame>Day 28 T0 (08:00 Â±30 mins), T0+2 hrs, T0+4 hrs, T0+8 hrs</time_frame>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Glaucoma and Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Low Dose DE-117</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium Dose DE-117</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose DE-117</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose DE-117 and 0.0015% tafluprost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adjunctive Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Med. Dose DE-117 and 0.0015% tafluprost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adjunctive Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose DE-117 and 0.0015% tafluprost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adjunctive Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.0015% tafluprost</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DE-117</intervention_name>
    <description>Ophthalmic Solution, QD, 28 Days</description>
    <arm_group_label>Low Dose DE-117</arm_group_label>
    <arm_group_label>Medium Dose DE-117</arm_group_label>
    <arm_group_label>High Dose DE-117</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.0015% tafluprost</intervention_name>
    <description>Ophthalmic Solution, QD, 28 days</description>
    <arm_group_label>0.0015% tafluprost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DE-117 and 0.0015% tafluprost</intervention_name>
    <description>Ophthalmic Solutions, QD, 28 days</description>
    <arm_group_label>Low Dose DE-117 and 0.0015% tafluprost</arm_group_label>
    <arm_group_label>Med. Dose DE-117 and 0.0015% tafluprost</arm_group_label>
    <arm_group_label>High Dose DE-117 and 0.0015% tafluprost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Ophthalmic Solution, QD, 28 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or Female, 18 years of age or older

          2. Current diagnosis of primary open-angle glaucoma or ocular hypertension in both eyes

          3. Qualifying intraocular pressure (IOP) in at least one eye at Baseline

        Exclusion Criteria:

          1. Closed/barely open anterior chamber angle or a history of acute angle closure in
             either eye

          2. Anticipate the need to initiate or modify medication (systemic or topical) that is
             known to affect intraocular pressure (IOP) during the study period

          3. Females who are pregnant, nursing or planning a pregnancy

          4. Presence of any abnormality or significant illness that could be expected to interfere
             with the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Santen Investigational Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santen Investigational Site</name>
      <address>
        <city>Deerfield Beach</city>
        <state>Florida</state>
        <zip>33064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santen Investigational Site</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33773</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santen Investigational Site</name>
      <address>
        <city>Morrow</city>
        <state>Georgia</state>
        <zip>30260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santen Investigational Site</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santen Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santen Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santen Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santen Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santen Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2012</study_first_submitted>
  <study_first_submitted_qc>July 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2012</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

